Franciosi Luigi G, Page Clive P, Celli Bartolome R, Cazzola Mario, Walker Michael J, Danhof Meindert, Rabe Klaus F, Della Pasqua Oscar E
Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands.
Respir Res. 2006 May 10;7(1):74. doi: 10.1186/1465-9921-7-74.
Patients with chronic obstructive pulmonary disease (COPD) can experience 'exacerbations' of their conditions. An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management. There is a need for reliable markers that reflect the pathological mechanisms that underlie exacerbation severity and that can be used as a surrogate to assess treatment effects in clinical studies. Little is known as to how existing study variables and suggested markers change in both the stable and exacerbation phases of COPD. In an attempt to find the best surrogates for exacerbations, we have reviewed the literature to identify which of these markers change in a consistent manner with the severity of the exacerbation event.
We have searched standard databases between 1966 to July 2004 using major keywords and terms. Studies that provided demographics, spirometry, potential markers, and clear eligibility criteria were included in this study. Central tendencies and dispersions for all the variables and markers reported and collected by us were first tabulated according to sample size and ATS/ERS 2004 Exacerbation Severity Levels I to III criteria. Due to the possible similarity of patients in Levels II and III, the data was also redefined into categories of exacerbations, namely out-patient (Level I) and in-patient (Levels II & III combined). For both approaches, we performed a fixed effect meta-analysis on each of the reported variables.
We included a total of 268 studies reported between 1979 to July 2004. These studies investigated 142,407 patients with COPD. Arterial carbon dioxide tension and breathing rate were statistically different between all levels of exacerbation severity and between in out- and in-patient settings. Most other measures showed weak relationships with either level or setting, or they had insufficient data to permit meta-analysis.
Arterial carbon dioxide and breathing rate varied in a consistent manner with exacerbation severity and patient setting. Many other measures showed weak correlations that should be further explored in future longitudinal studies or assessed using suggested mathematical modelling techniques.
慢性阻塞性肺疾病(COPD)患者会经历病情“急性加重”。急性加重是根据主观描述或症状定义的事件,即呼吸困难、咳嗽和咳痰加重到足以需要改变医疗管理的程度。需要可靠的标志物来反映急性加重严重程度背后的病理机制,并可在临床研究中用作评估治疗效果的替代指标。关于现有研究变量和建议的标志物在COPD稳定期和急性加重期如何变化,人们了解甚少。为了找到急性加重的最佳替代指标,我们回顾了文献,以确定这些标志物中哪些与急性加重事件的严重程度呈一致变化。
我们在1966年至2004年7月期间使用主要关键词和术语搜索了标准数据库。本研究纳入了提供人口统计学、肺功能测定、潜在标志物和明确纳入标准的研究。我们报告和收集的所有变量和标志物的集中趋势和离散度首先根据样本量和美国胸科学会/欧洲呼吸学会2004年急性加重严重程度I至III级标准制成表格。由于II级和III级患者可能存在相似性,数据也被重新定义为急性加重类别,即门诊(I级)和住院(II级和III级合并)。对于这两种方法,我们对每个报告的变量进行了固定效应荟萃分析。
我们共纳入了1979年至2004年7月期间报告的268项研究。这些研究调查了142407例COPD患者。动脉血二氧化碳分压和呼吸频率在所有急性加重严重程度级别之间以及门诊和住院患者之间存在统计学差异。大多数其他指标与级别或环境的关系较弱,或者数据不足无法进行荟萃分析。
动脉血二氧化碳和呼吸频率与急性加重严重程度和患者环境呈一致变化。许多其他指标显示出较弱的相关性,应在未来的纵向研究中进一步探索,或使用建议的数学建模技术进行评估。